Amphastar Pharmaceuticals Inc (AMPH)
41.15
+0.32
(+0.78%)
USD |
NASDAQ |
Apr 26, 15:31
Amphastar Pharmaceuticals Enterprise Value: 2.297B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 2.297B |
| April 24, 2024 | 2.305B |
| April 23, 2024 | 2.301B |
| April 22, 2024 | 2.265B |
| April 19, 2024 | 2.258B |
| April 18, 2024 | 2.192B |
| April 17, 2024 | 2.259B |
| April 16, 2024 | 2.300B |
| April 15, 2024 | 2.295B |
| April 12, 2024 | 2.239B |
| April 11, 2024 | 2.264B |
| April 10, 2024 | 2.259B |
| April 09, 2024 | 2.300B |
| April 08, 2024 | 2.308B |
| April 05, 2024 | 2.343B |
| April 04, 2024 | 2.330B |
| April 03, 2024 | 2.350B |
| April 02, 2024 | 2.369B |
| April 01, 2024 | 2.422B |
| March 28, 2024 | 2.445B |
| March 27, 2024 | 2.426B |
| March 26, 2024 | 2.411B |
| March 25, 2024 | 2.432B |
| March 22, 2024 | 2.435B |
| March 21, 2024 | 2.475B |
| Date | Value |
|---|---|
| March 20, 2024 | 2.451B |
| March 19, 2024 | 2.477B |
| March 18, 2024 | 2.394B |
| March 15, 2024 | 2.404B |
| March 14, 2024 | 2.410B |
| March 13, 2024 | 2.428B |
| March 12, 2024 | 2.457B |
| March 11, 2024 | 2.440B |
| March 08, 2024 | 2.530B |
| March 07, 2024 | 2.582B |
| March 06, 2024 | 2.561B |
| March 05, 2024 | 2.610B |
| March 04, 2024 | 2.578B |
| March 01, 2024 | 2.556B |
| February 29, 2024 | 2.573B |
| February 28, 2024 | 2.966B |
| February 27, 2024 | 3.000B |
| February 26, 2024 | 2.983B |
| February 23, 2024 | 2.902B |
| February 22, 2024 | 2.830B |
| February 21, 2024 | 2.797B |
| February 20, 2024 | 2.854B |
| February 16, 2024 | 2.932B |
| February 15, 2024 | 3.002B |
| February 14, 2024 | 2.974B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
593.31M
Minimum
Mar 20 2020
3.514B
Maximum
Aug 08 2023
1.412B
Average
1.008B
Median
May 22 2019
Enterprise Value Benchmarks
| Eli Lilly and Co | 711.57B |
| Dentsply Sirona Inc | 8.078B |
| Pacira BioSciences Inc | 1.430B |
| Organon & Co | 12.78B |
| NovaBay Pharmaceuticals Inc | 2.275M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 36.17M |
| Revenue (Quarterly) | 178.10M |
| Total Expenses (Quarterly) | 124.12M |
| EPS Diluted (Quarterly) | 0.68 |
| Gross Profit Margin (Quarterly) | 53.98% |
| Profit Margin (Quarterly) | 20.31% |
| Earnings Yield | 6.27% |
| Operating Earnings Yield | 9.03% |
| Normalized Earnings Yield | 6.270 |